Class II drugs are β-adrenergic receptor antagonists.
Action:
These agents have the ability of decreasing Phase 4 depolarization thus suppresses the automaticity, causing a prolonged AV conduction and decreased cardiac rate and contractility.
Therapeutic uses:
Class II drugs are used in the treatment of tachycardia due to promoted activity of sympathetic system.
They are also useful in the treatment of atrial flutter and fibrillation.
They are used in AV nodal re-entrant tachycardia.
Sunday, March 6, 2011
Propafenone
Same as that of flecainide. It has the ability of allowing conduction in all the tissues of heart.
Flecainide
It binds to sodium channels and slowly detaches from sodium channels.
Mechanism of action:
It is a sodium channel blocker. It suppresses phase 0 of action potential in purkinje fibers and fibers of the muscles of the heart.
Actions:
It does not affect greatly the action potential.
1. In this case, automaticity of the ectopic pacemaker is decreased by the promoted threshold potential (not by a reduction in the slope of phase 4 depolarization).
2. It causes a decreased conduction and excitability and promoted refractory period (pronounced in the depolarized tissue).
Pharmacokinetics:
It is absorbed orally and it has a half life of about 16-20 hours.
Therapeutic uses:
1. It is used in premature ventricular contractions, refractory ventricular tachycardia and supraventricular tachycardia.
2. It is used for the inhibition of sudden outburst of atrial fibrillation or flutter.
Adverse effects:
It may cause dizziness, blurred vision, anorexia, nausea, vomiting, impotence and in some cases may worsen preexisting arrhythmias.
Mechanism of action:
It is a sodium channel blocker. It suppresses phase 0 of action potential in purkinje fibers and fibers of the muscles of the heart.
Actions:
It does not affect greatly the action potential.
1. In this case, automaticity of the ectopic pacemaker is decreased by the promoted threshold potential (not by a reduction in the slope of phase 4 depolarization).
2. It causes a decreased conduction and excitability and promoted refractory period (pronounced in the depolarized tissue).
Pharmacokinetics:
It is absorbed orally and it has a half life of about 16-20 hours.
Therapeutic uses:
1. It is used in premature ventricular contractions, refractory ventricular tachycardia and supraventricular tachycardia.
2. It is used for the inhibition of sudden outburst of atrial fibrillation or flutter.
Adverse effects:
It may cause dizziness, blurred vision, anorexia, nausea, vomiting, impotence and in some cases may worsen preexisting arrhythmias.
Mexiletine and tocainide
Subscribe to:
Posts (Atom)
-
It is the loss of water from a crystal. It means “to flower out” in French. It is the spontaneous loss of water (or solvent) from a hyd...
-
Q: What do you know about ergot alkaloids? Ans: These include alkaloids which we get from the ergot fungus Claviceps purpurea or derived ...
-
(For detailed study of Pharmaceutical Incompatibility Click here) Multiple Choice Questions (MCQs) from Pharmaceutical Incompatibility in ...